DE60224299T2 - Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor - Google Patents

Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor Download PDF

Info

Publication number
DE60224299T2
DE60224299T2 DE60224299T DE60224299T DE60224299T2 DE 60224299 T2 DE60224299 T2 DE 60224299T2 DE 60224299 T DE60224299 T DE 60224299T DE 60224299 T DE60224299 T DE 60224299T DE 60224299 T2 DE60224299 T2 DE 60224299T2
Authority
DE
Germany
Prior art keywords
methyl
fluorine
hydrogen
epothilone
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60224299T
Other languages
German (de)
English (en)
Other versions
DE60224299D1 (de
Inventor
Ying-Nan Pan Parsippany CHEN
Peter Succasunna LASSOTA
Alexander Wallace Ho Ho Kus WOOD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of DE60224299D1 publication Critical patent/DE60224299D1/de
Publication of DE60224299T2 publication Critical patent/DE60224299T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60224299T 2001-10-25 2002-10-24 Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor Expired - Lifetime DE60224299T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US34473401P 2001-10-25 2001-10-25
US34473501P 2001-10-25 2001-10-25
US344735P 2001-10-25
US344734P 2001-10-25
US33603301P 2001-11-15 2001-11-15
US336033P 2001-11-15
PCT/EP2002/011924 WO2003035047A2 (en) 2001-10-25 2002-10-24 Combinations comprising a selective cyclooxygenase-2 inhibitor

Publications (2)

Publication Number Publication Date
DE60224299D1 DE60224299D1 (de) 2008-02-07
DE60224299T2 true DE60224299T2 (de) 2008-12-11

Family

ID=27407094

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60224299T Expired - Lifetime DE60224299T2 (de) 2001-10-25 2002-10-24 Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor

Country Status (22)

Country Link
US (2) US20050043409A1 (enExample)
EP (1) EP1441714B1 (enExample)
JP (1) JP2005506366A (enExample)
KR (1) KR100954625B1 (enExample)
CN (1) CN100506224C (enExample)
AT (1) ATE381930T1 (enExample)
AU (2) AU2006252156A1 (enExample)
BR (1) BR0213486A (enExample)
CA (1) CA2464309C (enExample)
CY (1) CY1108045T1 (enExample)
DE (1) DE60224299T2 (enExample)
DK (1) DK1441714T3 (enExample)
ES (1) ES2295428T3 (enExample)
HU (1) HUP0600235A3 (enExample)
IL (1) IL161462A0 (enExample)
MX (1) MXPA04003878A (enExample)
NZ (2) NZ552335A (enExample)
PL (1) PL369305A1 (enExample)
PT (1) PT1441714E (enExample)
RU (1) RU2333754C2 (enExample)
SI (1) SI1441714T1 (enExample)
WO (1) WO2003035047A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
ATE412655T1 (de) 2003-08-29 2008-11-15 Pfizer Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
JP2007505938A (ja) * 2003-09-23 2007-03-15 ノバルティス アクチエンゲゼルシャフト Ｖｅｇｆ受容体阻害剤と化学療法剤の組み合わせ
EP1667721A2 (en) * 2003-09-23 2006-06-14 Novartis AG Combinations of a vegf receptor inhibitor with other therapeutic agents
AP2006003619A0 (en) 2003-12-23 2006-06-30 Pfizer Novel quinoline derivatives
JO2596B1 (en) * 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
WO2007091622A1 (ja) * 2006-02-09 2007-08-16 Daiichi Sankyo Company, Limited 抗癌医薬組成物
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
CA2855243C (en) 2011-11-11 2020-04-14 Novartis Ag Method of treating a proliferative disease
MD565Z (ro) * 2012-05-23 2013-07-31 Институт Генетики, Физиологии И Защиты Растений Академии Наук Молдовы Procedeu de tratare a seminţelor de sfeclă de zahăr

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2224222T3 (es) * 1996-10-15 2005-03-01 G.D. Searle Llc Metodo de uso de inhibidores de la ciclooxigenasa-2 en el tratamiento y prevencion de neoplasias.
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
NZ333399A (en) * 1997-12-24 2000-05-26 Sankyo Co Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
AU783992B2 (en) * 1998-12-23 2006-01-12 G.D. Searle Llc Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
NZ517120A (en) * 1999-08-12 2004-10-29 Wyeth Corp NSAID and EFGR kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
DZ3246A1 (fr) * 1999-12-03 2001-06-07 Pfizer Prod Inc Dérivé heterocyclo-alkylsulfonyle pyrazole en tant qu'agents anti-inflammatoires/analgesiques
ITMI992711A1 (it) * 1999-12-27 2001-06-27 Novartis Ag Composti organici
EP1259237A4 (en) * 2000-02-17 2004-07-28 Merck & Co Inc TREATMENT AND PROPHYLAXIS OF PROSTATE CANCER WITH COX-2 SELECTIVE INHIBITORS
CA2400923A1 (en) * 2000-02-25 2001-08-30 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2003525288A (ja) * 2000-03-03 2003-08-26 ファイザー・プロダクツ・インク 抗炎症剤／鎮痛剤としてのピラゾールエーテル誘導体
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer

Also Published As

Publication number Publication date
BR0213486A (pt) 2005-05-10
AU2010200433A1 (en) 2010-02-25
ATE381930T1 (de) 2008-01-15
ES2295428T3 (es) 2008-04-16
PT1441714E (pt) 2008-03-10
HUP0600235A2 (en) 2007-02-28
WO2003035047A2 (en) 2003-05-01
CY1108045T1 (el) 2013-09-04
US20050043409A1 (en) 2005-02-24
CA2464309A1 (en) 2003-05-01
PL369305A1 (en) 2005-04-18
IL161462A0 (en) 2004-09-27
WO2003035047A3 (en) 2003-10-23
CA2464309C (en) 2012-01-03
AU2006252156A1 (en) 2007-01-18
HK1068261A1 (en) 2005-04-29
NZ552335A (en) 2008-11-28
CN1575168A (zh) 2005-02-02
RU2004116069A (ru) 2005-06-10
US20110046190A1 (en) 2011-02-24
DK1441714T3 (da) 2008-03-31
KR20040048992A (ko) 2004-06-10
RU2333754C2 (ru) 2008-09-20
NZ532418A (en) 2007-02-23
MXPA04003878A (es) 2004-07-08
DE60224299D1 (de) 2008-02-07
KR100954625B1 (ko) 2010-04-27
EP1441714A2 (en) 2004-08-04
EP1441714B1 (en) 2007-12-26
SI1441714T1 (sl) 2008-06-30
CN100506224C (zh) 2009-07-01
JP2005506366A (ja) 2005-03-03
HUP0600235A3 (en) 2008-04-28

Similar Documents

Publication Publication Date Title
DE60130017T2 (de) Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität
DE69400799T2 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE3779500T2 (de) Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
DE60127970T2 (de) Zusammensetzung, welche ein antifolate und ein methylmalonsäuresenkendes mittel enthält
DE60214846T2 (de) Verwendung von mGLuR5 antagonists zur Herstellung von Medikamenten zur Behandlung von empfindlichen X Syndrome, Autismus und geistiger Zurückgebliebenheit
DE69828881T2 (de) Zusammensetzung zur linderung von störungen der stimmungslage bei gesunden individuen
DE60004348T2 (de) Kombinierte vorbereitungen, die morpholin anthracyclin und platin derivate
DE60224299T2 (de) Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor
DE60017878T2 (de) Kombinationspräparate zur behandlung von erkrankungen, die mit angiogenese verbunden sind
EP1093369A2 (de) Mittel mit antidepressiver wirkung, enthaltend pramipexol und ein weiteres antidepressivum
DE60315258T2 (de) Behandlung von nicht-schmerzhaften blasenstörungen mit modulatoren der alpha-2-delta-untereinheit des calciumkanals
DE60210488T2 (de) Verwendung von hydroxyölsäure und ähnlicher verbindungen bei der herstellung von medikamenten
DE69329062T2 (de) Verwendung von inhibitoren der 3-hydroxy-3-methylglutaryl-coenzym a-reduktase als mittel zur krebstherapie
DE60212710T2 (de) Pharmazeutische zubereitungen enthaltend epothilone und deren verwendung bei der behandlung von karzinoid
DE10163667B4 (de) Verwendung von Desoxypeganin zur Behandlung der klinischen Depression
DE69930624T2 (de) Arzneimittel für hinterstrangataxie und zusammensetzung zur behandlung von hinterstrangataxie
DD242749A5 (de) Verbesserte entzuendungshemmende zusammensetzungen und verfahren
DE60200101T2 (de) Kombination von acetyldinalin und docetaxel
DE60316775T2 (de) Kombinationspräparat aus epothilone derivate und imidazotetrazinone
EP1001756A1 (de) Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe
DE60100431T2 (de) Arzneistoffkombination zur behandlung von kopfschmerzen mit mirtazapine und paracetamol oder nicht-steroiden entzündungshemmenden mitteln
DE3116859A1 (de) Therapeutische zubereitungen fuer die behandlung einer tardiven dyskinesie
DE19629802A1 (de) Arzneimittel zur Behandlung von Neuropathien
DE60310975T2 (de) Verwendung von epothilone zur behandlung hyperparathyreoidismus
DE10318714B4 (de) Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN